Cure My Disease

Don't miss your cure!

 Log in / Sign up

Texting away UTIs: could a phone platform cut unnecessary antibiotics?

NCT ID NCT06035601

Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether an EHR-integrated texting platform, called Urotrust, can help women with recurrent urinary tract infections (UTIs) manage their condition better than usual care. The platform provides symptom triage, clinical guidance, and prevention education via text messages, along with standing orders for urine tests. The main goal is to see if it reduces unnecessary antibiotic prescriptions, while also improving patients' confidence in managing their UTIs. Participants are women aged 18 and older who receive care at Penn Urogynecology or Penn Urology and own a mobile phone with texting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EHR-integrated texting platform (Urotrust) providing symptom triage, prevention education, and standing orders for urine tests
What this could lead to
If effective, this platform could reduce unnecessary antibiotic use and empower women to better manage recurrent UTIs, potentially lowering healthcare costs and antibiotic resistance.
What could go wrong
This is a relatively small trial, and the platform's success depends on user engagement and adherence. It may not generalize to all populations or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

102 people

The number who actually took part.

Started

Mar 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Females who currently meet the criteria for recurrent UTIs 4. Age 18 years or older 5. Owns a mobile device with text messaging capability 6. Ability to read and write English 7. Currently receiving care from a provider in Penn Urogynecology or Penn Urology Exclusion criteria: 1. History of known multidrug resistant UTIs 2. History of interstitial cystitis/bladder pain syndrome or current diagnosis of chronic pelvic pain 3. On continuous suppressive antibiotics currently 4. Currently pregnant or within 6 weeks of pregnancy 5. Transplant patient on immunosuppressive medication currently 6. Practice of chronic self-catheterization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent urinary tract infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary tract infection urinary tract infections, recurrent, susceptibility to

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent urinary tract infection

Contacts and locations

Locations

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.